ES2187598T3 - Metodos para producir proteinas de fusion. - Google Patents

Metodos para producir proteinas de fusion.

Info

Publication number
ES2187598T3
ES2187598T3 ES96113414T ES96113414T ES2187598T3 ES 2187598 T3 ES2187598 T3 ES 2187598T3 ES 96113414 T ES96113414 T ES 96113414T ES 96113414 T ES96113414 T ES 96113414T ES 2187598 T3 ES2187598 T3 ES 2187598T3
Authority
ES
Spain
Prior art keywords
site
dna sequence
transformed
methods
breaking
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96113414T
Other languages
English (en)
Inventor
Stephen D Gillies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of ES2187598T3 publication Critical patent/ES2187598T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE DESCRIBEN METODOS DE PRODUCCION DE PROTEINAS DE FUSION, INCLUYENDO AQUELLAS CON ACTIVIDADES BIOLOGICAS DUALES. DICHOS METODOS INCLUYEN: LA PROVISION DE UNA PRIMERA Y UNA SEGUNDA SECUENCIAS DE ADN, QUE CODIFICAN PARA UN PRIMER Y UN SEGUNDO POLIPEPTIDOS, RESPECTIVAMENTE; LA DIGESTION DE LA PRIMERA SECUENCIA DE ADN EN UN SITIO DE RESTRICCION ADYACENTE A SU EXTREMO 5''; Y LA UNION DE UNA SECUENCIA DE CONEXION/ADAPTADORA (1/A), AL EXTREMO DE RESTRICCION DE LA PRIMERA SECUENCIA DE ADN, FORMANDOSE POR TANTO UNA CASETE. LA 1/A INCLUYE, EN UN EXTREMO, LA PORCION DE LA PRIMERA SECUENCIA DE ADN QUE SE EXTIENDE DESDE SU EXTREMO MAS CERCANO AL SITIO DE RESTRICCION, HASTA EL SITIO DE RESTRICCION, Y, EN EL OTRO EXTREMO, UNA HEBRA DE UN SITIO DE RUPTURA. SE TRANSFORMA UNA CELULA HUESPED EUCARIOTICA, CON LA CITADA CASETE, Y LA SEGUNDA SECUENCIA DE ADN, QUE TIENE EN UN EXTREMO UNA HEBRA DEL SITIO DE RUPTURA, COMPATIBLE CON LA HEBRA DEL SITIO DE RUPTURA EN 1/A. LA CELULA HUESPED TRANSFORMADA, SE CULTIVA PARA EXPRESAR EL ADN TRANSFORMADO COMO UNA PROTEINA DE FUSION DE CADENA UNICA.
ES96113414T 1989-09-20 1990-08-01 Metodos para producir proteinas de fusion. Expired - Lifetime ES2187598T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40988989A 1989-09-20 1989-09-20

Publications (1)

Publication Number Publication Date
ES2187598T3 true ES2187598T3 (es) 2003-06-16

Family

ID=23622388

Family Applications (2)

Application Number Title Priority Date Filing Date
ES96113414T Expired - Lifetime ES2187598T3 (es) 1989-09-20 1990-08-01 Metodos para producir proteinas de fusion.
ES90913419T Expired - Lifetime ES2103274T3 (es) 1989-09-20 1990-08-01 Metodo de produccion de proteinas de fusion.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES90913419T Expired - Lifetime ES2103274T3 (es) 1989-09-20 1990-08-01 Metodo de produccion de proteinas de fusion.

Country Status (9)

Country Link
EP (2) EP0765937B1 (es)
JP (1) JP3051162B2 (es)
AT (2) ATE228566T1 (es)
AU (1) AU633357B2 (es)
CA (1) CA2066612C (es)
DE (2) DE69034022T2 (es)
DK (2) DK0765937T3 (es)
ES (2) ES2187598T3 (es)
WO (1) WO1991004329A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5747334A (en) * 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
CA2094495C (en) * 1990-10-22 2007-04-03 David Botstein Methods for modifying and detecting the effects on the interaction of modified polypeptides and target substrates
US5525491A (en) * 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
CA2128511C (en) * 1992-01-23 2006-11-07 Andreas Pluckthun Monomeric and dimeric antibody-fragment fusion proteins
US6103521A (en) * 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
DE60025829T2 (de) * 1999-07-12 2006-11-02 Genentech, Inc., South San Francisco Expressionsvektoren und anwendungsmethoden
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001010912A1 (en) 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
CZ2003214A3 (cs) 2000-06-29 2003-08-13 Merck Patent Gmbh Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
DK1366067T3 (da) * 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
BR0209177A (pt) 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
EP1454138B1 (en) 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
ATE471946T1 (de) 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
KR101163424B1 (ko) 2003-12-30 2012-07-13 메르크 파텐트 게엠베하 Ｉｌ－７ 융합 단백질
EP1699821B1 (en) 2003-12-31 2012-06-20 Merck Patent GmbH Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
CA2553883C (en) 2004-01-22 2013-04-02 Merck Patent Gesellschaft Mit Beschraenkter Haftung Anti-cancer antibodies with reduced complement fixation
CN101072793B (zh) 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
AU2006272555B2 (en) 2005-07-25 2012-03-08 Aptevo Research And Development Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
SI1966238T1 (sl) 2005-12-30 2012-08-31 Merck Patent Gmbh Variante interlevkina-12P40 z izboljšano stabilnostjo
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
US10071748B2 (en) 2015-09-17 2018-09-11 Sony Corporation System and method for providing driving assistance to safely overtake a vehicle
HK1251480A1 (zh) 2015-09-21 2019-02-01 Aptevo Research And Development Llc Cd3结合多肽
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN110592057B (zh) * 2019-09-27 2022-01-28 昆明理工大学 嵌合裂解酶ILTphg和编码此酶的多核苷酸
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4771002A (en) * 1984-02-24 1988-09-13 Lubrizol Genetics, Inc. Transcription in plants and bacteria

Also Published As

Publication number Publication date
WO1991004329A1 (en) 1991-04-04
ATE228566T1 (de) 2002-12-15
ATE152174T1 (de) 1997-05-15
ES2103274T3 (es) 1997-09-16
CA2066612C (en) 1998-12-08
DE69034022D1 (de) 2003-01-09
DE69030579T2 (de) 1997-11-13
DK0493418T3 (da) 1997-11-03
EP0493418B1 (en) 1997-04-23
AU633357B2 (en) 1993-01-28
EP0765937B1 (en) 2002-11-27
CA2066612A1 (en) 1991-03-21
EP0493418A4 (en) 1992-09-02
JP3051162B2 (ja) 2000-06-12
AU6335290A (en) 1991-04-18
EP0493418A1 (en) 1992-07-08
JPH05500310A (ja) 1993-01-28
EP0765937A1 (en) 1997-04-02
DE69034022T2 (de) 2003-07-10
DE69030579D1 (de) 1997-05-28
DK0765937T3 (da) 2003-03-24

Similar Documents

Publication Publication Date Title
ES2103274T3 (es) Metodo de produccion de proteinas de fusion.
ES2094111T3 (es) Proteinas con actividad de factor viii, procedimiento para su produccion que utilizan celulas modificadas por ingenieria genetica y composiciones farmaceuticas que las contienen.
ES8602121A1 (es) Procedimiento para producir un vehiculo de expresion para la formacion de uroquinasa humana
ATE132902T1 (de) Humane mangan-superoxiddismutase (hmn-sod)
WO2002031134A3 (en) Novel serine protease genes related to dppiv
BR0014945A (pt) Modificação pós-traducional de proteìnas recombinantes produzidas em plantas
AR006250A1 (es) Compuestos y metodos para la inmunoterapia e inmunodiagnostico del cancer prostatico
ES2152233T3 (es) Fragmento de dna que codifica una aox.
ES2072900T3 (es) Expresion elevada de proteinas en levadura.
ES2056817T3 (es) Transformacion de trichoderma.
ES9000011A1 (es) Procedimiento para transformar un cultivo de celulas de modo que produzca activador de plasminogeno de tejido (t-pa) humano
ES2073735T3 (es) Nuevos analogos de la cadena b del factor de crecimiento derivado de plaquetas y metodo para su produccion homogenea.
ES2059361T3 (es) Complejo de proteinas recombinantes que tiene actividad de factor viii:c su produccion y uso.
ES2010538A6 (es) Procedimiento para la preparacion de un gen sintetico.
DK215287D0 (da) Dna-sekvenser, der koder for et protein med angiogen virkning, vektorer, vaertsceller og fremgangsmaader til udtrykkelse af proteinet, samt laegemidler indeholdende dette
ES2144399T3 (es) Clonado del adn de virus de anemia de los pollos.
ES2068201T3 (es) Produccion de kalicreina.
ES2104596T3 (es) Nuevos polipeptidos, secuencias de adn que permiten su expresion, metodo de preparacion, y utilizacion.
ES2026206T3 (es) Procedimiento para mejorar la expresion de proteina de eucariota.
DK1082423T3 (da) Cyclin E2-gener og -proteiner
ES2043610T3 (es) Procedimiento para la produccion de un polipeptido hibrido del tipo activador de plasminogeno.
ES2048142T3 (es) Procedimiento de obtencion de polidesoxirribonucleotidos sustancialmente puros y no informacionales que tienen actividades biologicas, y producto respectivo.
ATE408631T1 (de) Chimäres protein welches eine intramolekulare chaperon-ähnliche sequenz enthält und dessen anwendung zur insulinproduktion
KR880014107A (ko) 안지오게닌의 유전공학적 제조방법
FI913266A0 (fi) Foerfarande foer infoerande av exogen dna i djurets somatiska och groddceller.